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Healing times following treatment with antibiotics, and factors that influence healing, have
not been reported in Australian patients with Mycobacterium ulcerans.
Methodology/Principal findings
Healing times were determined for all M. ulcerans cases treated by a single physician with
antibiotics at Barwon Health, Victoria, from 1/1/13-31/12/16. Lesions were categorised by
induration size: category A 400mm2, Category B 401-1600mm2 and Category C
1601mm2. A logistic regression analysis was performed to determine risk factors for pro-
longed wound healing (>150 days from antibiotic commencement).
163 patients were included; 92 (56.4%) were male and median age was 58 years (IQR
39–73 years). Baseline lesion size [available in 145 (89.0%) patients] was categorised as A
in 46 (31.7%), B in 67 (46.2%) and C in 32 (22.1%) patients. Fifty (30.7%) patients had sur-
gery. In those treated with antibiotics alone, 83.0% experienced a reduction in induration
size after 2 weeks, then 70.9% experienced an increase in induration size from the lowest
point, and 71.7% experienced an increase in ulceration size. A linear relationship existed
between the time induration resolved and wound healing began.
Median time to heal was 91 days (IQR 70–148 days) for category A lesions; significantly
shorter than for category B lesions (128 days, IQR 91–181 days, p = 0.05) and category C
lesions (169 days, IQR 159–214 days, p<0.001). Fifty-seven (35.0%) patients experienced
a paradoxical reaction. Of those treated with antibiotics alone, lesions experiencing a para-
doxical reaction had longer healing times [median time to heal 177 days (IQR 154–224
days) compared to 107 days (IQR 79–153 days), p<0.001]. On multivariable logistic regres-
sion, lesion size at baseline (p<0.001) and paradoxical reactions (p<0.001) were indepen-
dently associated with prolonged healing times.
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For category A and B lesions, healing time was significantly shorter with antibiotics plus
excision and direct closure compared with antibiotics alone [Category A lesions median 55
days (IQR 21–63 days) compared with 91 days (IQR 70–148 days), p<0.001; Category B
lesions median 74 days (IQR 21–121 days) compared to 128 days (IQR 97–181 days),
p<0.001].
Conclusions
In Australian patients treated with antibiotics M. ulcerans lesions usually initially improve,
then clinically deteriorate with increased induration and ulceration, before healing after the
inflammation associated with lesions resolves. The time to complete healing of lesions is
generally long, and is further prolonged in those with larger initial lesion size or who develop
paradoxical reactions. For small lesions (<4cm2), excisional surgery may reduce healing
times.
Author summary
In our study we have described for the first time in a large cohort of Australian patients
the natural history of wound healing of Mycobacterium ulcerans lesions following treat-
ment with antibiotics. We have shown that the lesions usually initially clinically improve
with a reduction in induration size, and then deteriorate with increased induration and
ulceration, prior to healing after the inflammation associated with lesions resolves. The
time to complete healing of lesions is generally long (on average 4.5 months), and is fur-
ther prolonged in those with increasing initial lesion size or in those who develop para-
doxical reactions. In some cases excisional surgery of lesions can reduce healing times by
1–2 months. Knowledge of the natural history of wound healing on antibiotics provides
important prognostic information for patients and clinicians when managing Mycobacte-
rium ulcerans disease. This information is also needed as a baseline to assess the impact of
new interventions aimed at improving healing times. Furthermore, knowledge of factors
that affect wound healing times may lead to interventions that significantly reduce them,
and in turn the quality and effectiveness of M. ulcerans treatment.
Introduction
Mycobacterium ulcerans (M. ulcerans) causes necrotising lesions of skin, soft-tissue and occa-
sionally bone that, if left untreated, usually progress and can lead to significant tissue loss, mor-
bidity and long-term deformity.[1, 2] It has been demonstrated that antibiotics are highly
effective at curing M. ulcerans lesions and preventing disease recurrence,[3–7] and oral antibi-
otics have reduced hospitalisations and the cost of treatment.[8] Despite antibiotics, healing
times can be prolonged, lasting up to 12 months after completion of the recommended 8-week
antibiotic regimen if skin defects are large.[6] Prolonged wound healing can lead to significant
expense and inconvenience as a result of the need for regular dressings and medical reviews,
can be disabling, and can lead to time off work or school resulting in both patient and health-
care provider dissatisfaction.
Healing times in Australian patients with M. ulcerans treated with antibiotics have not been
reported. Healing times in African patients have been reported,[6] but significant differences
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exist between Australian and African patients that may influence wound healing, with African
patients being younger, having fewer co-morbidities, and often less access to care including
surgical treatment and appropriate wound care.[9] Furthermore, risk factors for prolonged
healing times have not been studied. Knowledge of factors that affect wound healing times
may lead to interventions that significantly reduce them, and in turn improve the quality and
effectiveness of M. ulcerans treatment. Understanding the natural history of wound healing
with antibiotics provides important prognostic information for patients and clinicians when
managing this disease. It is also needed as a baseline to assess the impact of new interventions
aimed at improving healing times such as new dressing regimens, new medical treatments or
modifications to wound debriding techniques such as medical maggot therapy.
The aim of this study was to describe wound healing times in Australian patients with M. ulcer-
ans disease treated with antibiotics and to determine risk factors for prolonged healing times.
Methods
All M. ulcerans cases treated with antibiotics at Barwon Health, Victoria, from 1/1/13-31/12/16
by a single physician (DOB) were assessed for inclusion in the study. A M. ulcerans case was
defined as the presence of a lesion clinically suggestive of M. ulcerans plus any of [1] a culture
of M. ulcerans from the lesion, [2] a positive PCR from a swab or biopsy of the lesion, or [3]
histopathology of an excised lesion showing a necrotic ulcer with the presence of acid-fast
bacilli (AFB) consistent with acute M. ulcerans infection. The initial size of the lesion was
determined by measuring with a ruler the diameter of induration of lesions in millimetres and
calculating the surface area in millimetres squared. Lesions were catagorised by the size of
induration as follows: category A 400mm2, Category B 401-1600mm2 and Category C
1601mm2. These categories were chosen to allow specific study of small lesions (<2cm diam-
eter and 2–4 cm diameter), common in the Australian context, which would not have been
possible using World Health Organization categories. Lesion type and WHO category was
assigned according to published definitions.[10]
Wound healing was defined as complete re-epithelialisation of the wound. Healing time
was determined as the time from commencement of antibiotic treatment until full healing of
the lesion. This was determined by clinical assessment and the examination of photographs of
the lesion which could be provided by patients representing times between clinical visits.
Lesions were measured every 2 weeks whilst on antibiotics and every 4 weeks once antibiotics
were completed. Prolonged healing times were defined as time to healing of more than 150
days after antibiotic commencement.
Standard drug dosages for adults included rifampicin 10 mg/kg/day (up to a maximum of
600 mg daily), clarithromycin 7.5 mg/kg twice daily (up to 500 mg twice daily), ciprofloxacin
500 mg twice daily, and moxifloxacin 400 mg once daily. Surgical definitions were as follows:
a) curette: this involved a shallow surgical excision using a curette of the macroscopically
abnormal skin and subcutaneous tissue under local anaesthetic with the wound left open to
heal by secondary intention; b) debridement: this involved the debridement of necrotic or
inflamed tissue in the base of wounds and underlying the wound edges; c) excision and direct
closure: this involved excision of the lesion with direct closure of the skin defect; and d) exci-
sion and split skin graft (SSG): this involved excision of the lesion with direct closure of the
skin defect with a SSG. Treatment decisions were not standardized and were made on an indi-
vidual patient basis involving of a number of factors which included: initial size, site and type
of the lesion, patient co-morbidities and preferences, antibiotic contraindications and intoler-
ances, and lesion response to treatment. Wound care was not standardised and was provided
either by medical services or self-administered.
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Treatment success was defined as complete healing of the lesion without recurrence within
12 months of commencing antibiotic treatment. Paradoxical reactions were defined by the
presence of one or both of the following features: a) clinical: an initial improvement on antibi-
otic treatment in the clinical appearance of a M. ulcerans lesion followed by a clinically signifi-
cant deterioration of the lesion or its surrounding tissues in terms of oedema or tissue necrosis
as determined by a clinician experienced in the antibiotic treatment of M. Ulcerans (DOB), or
the appearance of a new lesion(s), and b) histopathology: examination of excised tissue from
the clinical lesion showing evidence of an intense inflammatory reaction consistent with a par-
adoxical reaction.[11]
Data analysis
Data was collected prospectively using Epi-info 6 (CDC, Atlanta) and analysed using STATA
12 (StataCorp, Texas, USA). Kernel density estimation methods were used to plot graphs of
whole cohort lesion responses to treatment with respect to induration and ulceration. Lowess
smoothing method was used to compare amount of induration and time to when healing
begins on a graph. Median values for non-parametric variables were compared using the Wil-
coxon rank-sum test. A logistic regression analysis was performed to determine crude odds
ratios of the association of variables with prolonged wound healing time. Variables with a
strong association on crude analysis (p0.20) were then included in a multivariable logistic
regression model to determine adjusted odds ratios for the association of variables with pro-
longed wound healing time. The p-values for assessing the strength of the association of each
variable with prolonged wound healing time, controlled for all the other variables in the
model, were determined by the likelihood ratio test.
Ethics
This study was approved by the Barwon Health Human Research and Ethics Committee. All
previously gathered human medical data were analysed in a de-identified fashion.
Results
Baseline characteristics
One hundred and eighty-five patients were treated with antibiotics by Barwon Health clini-
cians over the study period. Nineteen were managed by other physicians in BH, and three had
a lack of recorded data and were excluded. Thus 163 patients were included in the analysis.
Ninety-two (56.4%) were male and median age was 58 years (IQR 39–73 years). Baseline
lesion size prior to antibiotic treatment [available in 145 (89.0%) patients] was categorised as
A in 46 (31.7%), B in 67 (46.2%) and C in 32 (22.1%) patients. One hundred and eighteen
(72.4%) lesions were catagorised as WHO category 1, 20 (12.3%) as WHO category 2 and 25
(15.3%) as WHO category 3. One hundred and thirty-six (83.4%) lesions were ulcers, 11
(6.8%) nodules, 14 (8.6%) oedematous and 2 (1.2%) plaques. Thirty-nine (23.9%) lesions were
on upper limb, 119 (73.0%) lower limb, and 5 (3.1%) on the trunk, head or neck. Fifteen
(9.2%) patients had diabetes mellitus and 16 (9.9%) were immune suppressed.
Treatment
One hundred and thirteen (69.3%) patients had antibiotics alone, and 50 (30.7%) had antibiot-
ics plus surgery [4 (8%) curette, 15 (30%) debridement, 21 (42%) excision and direct closure,
and 10 (20%) excision + SSG]. The type of surgical treatment according to baseline size of
lesion is shown in Table 3.
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The median duration of antibiotic therapy was 56 days (IQR 46–56 days). Initial antibiotic
regimens were rifampicin and clarithromycin in 129 (79.1%), rifampicin and ciprofloxacin in
32 (19.0%), and rifampicin and moxifloxacin in 3 (1.8%).
Treatment outcomes
One hundred and fifty-eight (96.9%) patients experienced treatment success. Two patients
died prior to wound healing occurring (one of a cerebrovascular accident and one with haema-
temesis secondary to oesophageal varices). Three patients, all of whom experienced paradoxi-
cal reactions, took longer than 1 year to heal (392, 535 and 576 days), but all were cured of
their disease, with none requiring additional courses of antibiotics (1 had debridement sur-
gery). No patients experienced limitation of joint movements after wound healing.
Behaviour of M. ulcerans lesions during antibiotic treatment
In the first two weeks of antibiotic treatment, 98/118 (83.0%) of patients experienced a reduc-
tion in the size of induration associated with the lesion, with a median reduction of 49% (IQR
27–63%). (Fig 1) After an initial reduction in the size of induration of the lesion, 95/134
(70.9%) of patients then experienced an increase in the amount of induration from the lowest
point [median increase from lowest point 73% (IQR 31–163%)], (Fig 2) with 38/133 (28.6%) of
patients developing more induration than at baseline. After antibiotic commencement, 91/127
(71.7%) of patients experienced an increase in the size of the ulceration with a median
increased ulceration of 125% (IQR 47–400%). (Fig 3) The induration associated with lesions
resolved after a median of 95 days (IQR 56–145 days), and healing of wounds began after a
median of 77 days (IQR 42–112 days). There was a linear relationship between the time taken
for induration to resolve and the time for wound healing to begin (Fig 4).
Fig 1. Kernel density graph of percentage decrease in induration size after 2 weeks of antibiotic treatment of M.
ulcerans lesions.
https://doi.org/10.1371/journal.pntd.0006357.g001
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Fig 2. Kernel density graph of percentage increase in induration size from low point following antibiotic
treatment of M. ulcerans lesions.
https://doi.org/10.1371/journal.pntd.0006357.g002
Fig 3. Kernel density graph of percentage increase in ulceration size following antibiotic treatment of M. ulcerans
lesions.
https://doi.org/10.1371/journal.pntd.0006357.g003
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Wound healing
Wound healing: Antibiotics alone (Table 1). The time to wound healing was recorded
for 106 (93.8%) patients treated with antibiotics alone: five patients did not have accurate
information on time to wound healing, and two died prior to full wound healing, and were not
included in further analysis. The median time to heal was 138 days (IQR 91–175 days). Fourty-
eight (45.3%) had prolonged healing times, with 3 (2.8%) taking more than 12 months to heal.
The median time to heal was 91 days (IQR 70–148 days) for category A lesions, which was
significantly shorter than for category B lesions (128 days, IQR 91–181 days, p = 0.05) and cat-
egory C lesions (169 days, IQR 159–214 days, p<0.001). Median healing times were signifi-
cantly shorter for WHO category 1 lesions (119 days, IQR 84–160 days) compared with
Category 2 (169 days, IQR 154–214 days, p<0.001) or category 3 lesions (175 days, IQR 152–
219 days, p<0.01).
Median healing times were significantly longer for patients65 years of age compared to
those 15–64 years of age (p = 0.03). Compared to ulcerative lesions, oedematous lesions had
significantly longer healing times (p = 0.02). Median healing times were similar between gen-
ders, those with and without diabetes or immune suppression, lesion position, and antibiotic
regimen.
Risk factors for prolonged healing times with antibiotic treatment alone (Table 2). On
crude analysis, lesion size, age, and paradoxical reactions were significantly associated with
prolonged wound healing times. Gender, lesion position, lesion type, diabetes and drug
regimen were not associated with prolonged healing times. On a multivariable logistic regres-
sion, adjusting for age, gender and immune suppression, lesion size at baseline (p<0.001)
and paradoxical reactions (p<0.001) were independently associated with prolonged healing
times.
Fig 4. Lowess smoothing graph of time to healing begins related to time until induration resolves for antibiotic
treated M. ulcerans lesions.
https://doi.org/10.1371/journal.pntd.0006357.g004
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Wound healing: Antibiotics plus surgery (Table 3). The overall median time to heal fol-
lowing antibiotics plus surgery was 119 days (IQR 57–159 days). Median healing time was 71
days (IQR 64–114 days) if curette was performed, 137 days (IQR 117–243 days) if debridement
was performed, 55 days (IQR 21–113 days) if excision and direct closure was performed, and
152 days (IQR 121–223 days) if excision and SSG was performed.
For category A lesions, healing time was similar for those treated with antibiotics plus
curette compared with those treated with antibiotics alone (median 71 days with curette com-
pared with 91 days without curette, p = 0.32). However antibiotic treatment duration was
Table 1. Median healing times of M. ulcerans lesions treated with antibiotics alone according to baseline characteristics.
Variable Number of cases Median healing time, IQR (days) p-value
Lesion size
Cat A 31 91 (70–148) Comparator
Cat B 49 128 (97–181) 0.01
Cat C 21 169 (159–214) <0.001
WHO Category
1 83 119 (84–160) Comparator
2 14 169 (154–214) <0.001
3 9 175 (152–219) 0.03
Gender
Male 60 143 (93–171) 0.85
Female 46 135 (91–182)
Age (years)
0–15 8 113 (88–151) 0.75
16–64 57 119 (84–175) Comparator
65 41 156 (119–182) 0.03
Lesion Position
Upper limb 23 154 (77–202) Comparator
Lower limb 81 135 (92–175) 0.68
Trunk, head and neck 2 96 (84–108) 0.42
Lesion Type
Ulcer 99 137 (85–172) Comparator
Nodule 4 122 (108–174) 0.86
Oedema 2 321 (304–338) 0.02
Plaque 1 355 (355–355) 0.10
Diabetes
Yes 8 154 (140–182) 0.20
No 98 129 (85–175)
Immune Suppression
Yes 7 160 (90–168) 0.77
No 97 130 (91–179)
Paradoxical reaction
Yes 34 177 (154–224) <0.001
No 72 107 (79–153)
Drug regimen
Rifampicin/clarithromycin 86 136 (85–168) Comparator
Rifampicin/ciprofloxacin 19 153 (11–222) 0.08
Other regimen 1 70 (70–70) 0.24
https://doi.org/10.1371/journal.pntd.0006357.t001
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shorter for curetted patients [median 20.5 days (IQR 16.5–24.5 days) compared to 56 days
(IQR 56–56 days), p<0.01] with no difference in treatment outcomes.
For category A and B lesions, healing time was significantly shorter for those treated with
antibiotics plus excision and direct closure compared with those treated with antibiotics alone
[Category A lesions median 55 days (IQR 21–63 days) compared with 91 days (IQR 70–148
days), p<0.001, and Category B lesions median 74 days (IQR 21–121 days) compared to 128
days (IQR 97–181 days), p<0.001]. In addition, antibiotic treatment duration was shorter for
patients treated with excision and direct closure [median 28 days (IQR 25–42 days) compared
to 56 days (IQR 56–56 days), p<0.001] with no difference in treatment outcomes.
Table 2. Logistic regression model showing adjusted and unadjusted associations with baseline variables and prolonged healing times.
Variable Number (%) with prolonged
healing








Cat A 7 (22.6) 24 (77.4) 1 <0.001 1 <0.001
Cat B 21 (42.9) 28 (57.1) 2.6 (0.9,7.1) 2.6 (0.6,10.9)
Cat C 17 (81.0) 4 (19.1) 14.6 (3.7,57.7) 24.2 (3.8,155.0)
Gender
Female 19 (41.3) 27 (58.7) 1 0.47 1 0.40
Male 29 (48.3) 31 (51.7) 1.3 (0.6–2.9) 0.6 (0.2,2.0)
Age (years)
0–15 2 (25.0) 6 (75.0) 1 0.01 1 0.21
16–64 20 (35.1) 37 (64.9) 1.6 (0.3–8.8) 0.2 (0.0,1.8)
65 26 (63.4) 15 (36.6) 5.2 (0.93,29.1) 0.6 (0.1–4.4)
Lesion Position
Upper limb 13 (56.5) 10 (43.5) 1 0.23 - -
Lower limb 35 (43.2) 46 (56.8) 0.6 (0.2,1.5) - -
Trunk, head and neck 0 (0.0) 2 (100.0) N/A - -
Lesion Type
Ulcer 44 (44.4) 55 (55.6) 1 0.23 - -
Nodule 1 (25.0) 3 (75.0) 0.4 (0.0,4.1) - -
Oedema 2 (100.0) 0 (0.0) N/A - -
Plaque 1 (100.0) 0 (0.0) N/A - -
Diabetes
Yes 5 (62.5) 3 (37.5) 2.1 (0.5,9.4) 0.31 - -
No 43 (43.9) 55 (56.1) 1 - -
Immune Suppression
No 41 (42.3) 56 (57.7) 1 0.13 1 0.23
Yes 5 (71.3) 2 (28.6) 3.4 (0.6,18.5) 4.4 (0.4,47.9)
Paradoxical reaction
No 19 (26.4) 53 (73.6) 1 <0.001 1 <0.001




37 (43.1) 49 (57.0) 1 0.33 - -
Rifampicin/ciprofloxacin 11 (57.9) 8 (42.1) 1.82 (0.67,4.98) - -
Other regimen 0 (0.0) 1 (100.0) N/A - -
 Adjusted for age, gender, size of lesion, immune suppression and paradoxical reaction
https://doi.org/10.1371/journal.pntd.0006357.t002
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There was no significant difference in healing times for category B (p = 0.71) or category C
lesions (p = 0.24) treated with antibiotics plus surgical debridement compared with antibiotics
alone. However 75% of lesions treated with debridement experienced a paradoxical reaction.
Likewise there was no significant difference in healing times for category B (p = 0.48) or cate-
gory C lesions (p = 0.77) treated with antibiotics plus excision + SSG compared with antibiot-
ics alone.
Wound healing: Paradoxical reactions
Fifty-seven (35.0%) patients experienced a paradoxical reaction after a median 62 days (IQR
35–87 days) from start of antibiotic treatment. Twelve (21.0%) were diagnosed by clinical and
histological criteria and 45 (79.0%) on clinical criteria alone. Of those treated with antibiotics
alone, lesions affected by a paradoxical reaction had longer healing times than those not
experiencing a paradoxical reaction [median time to heal 177 days (IQR 154–224 days) com-
pared to 107 days (IQR 79–153 days), p<0.001]. This was true for each size category of lesion:
Median 165 days (IQR 139–206 days) compared to 84 days (IQR 70–119 days) for Category A
lesions (p<0.01), median 178 days (IQR 151–224 days) compared to 106 days (84–128 days)
for Category B lesions (p<0.001), and median 191 days (IQR 167–347 days) compared to 168
days (IQR 137–214 days) for Category C lesions (p = 0.06).
Discussion
We have described the natural history of M. ulcerans lesions following treatment with antibiot-
ics in Australian patients. We have shown that for the majority of lesions the following changes
occur: in the first weeks of treatment a significant reduction occurs in the size of induration
surrounding a lesion. Following this, the size of induration once again increases, and can often
become larger than at the start. Additionally, despite ongoing antibiotic treatment, the size of
the ulceration increases for most patients. Over time, the induration around the ulceration
resolves and at that time, but usually not before, the wound begins to heal. Total healing time
is long, with the majority of lesions taking more than 4 months to heal, and is longer in
patients with larger lesions or in those who experience paradoxical reactions.
In essence, the clinical appearance of the lesion usually gets worse on treatment, and lesions
will not have healed or improved greatly by the time the recommended antibiotic treatment (8
weeks) has been completed. Once the induration has settled the wound will begin to heal. This
information is very important for clinicians managing M. ulcerans as it will allow them to man-
age their own and their patient’s expectations as to how lesions respond to treatment. It will
hopefully also prevent them from mistakenly attributing lesion progression as treatment failure
and unnecessarily changing, prolonging or recommencing antibiotic treatment or recommend-
ing surgery in pursuit of disease cure. It also provides very important baseline data against
which interventions aimed at improving wound healing times can be studied in the future.
Interestingly, healing times of wounds after antibiotic treatment without surgery in our
Australian patients were similar to those reported from African patients. In a study by
Table 3. Type of surgical treatment according to baseline size of lesion.
Size category Curette Debridement Excision + direct closure Excision + SSG Total
A 4 0 9 0 13
B 0 6 6 2 14
C 0 6 0 4 10
Total 4 12 15 6 37
https://doi.org/10.1371/journal.pntd.0006357.t003
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Neinhuis et al in Ghana where patients were treated with antibiotic regimens of 8 weeks, the
time to complete wound healing was 18 weeks (95% CI 14–22 weeks) for category 1 lesions
and 30 weeks (95% CI 26–34 weeks) for category 2 and 3 lesions.[12] This compares to 17
weeks for category 1, 24 weeks for category 2 and 25 weeks for category 3 lesions in our study.
In addition, the behaviour of lesions following antibiotic treatment was similar with 78% of
lesions experiencing an increased in size of induration from the low point and in 30% of
lesions the amount of induration increased past the size at antibiotic commencement (com-
pared with 71% and 29% respectively in our study). In our study we have created a new
sub classification of WHO category 1 lesions as category A (400mm2) and Category B (401-
1600mm2) lesions, and we have shown that there are important differences as far as treatment
options (eg surgical interventions) and prognostic outcomes (eg healing times) between these
subgroups. We feel that in an Australian setting, where the majority of lesions are WHO cate-
gory 1 at presentation and surgical services are easily accessible, this is a relevant sub classifica-
tion and propose that this be considered for adoption in other contexts where it is relevant.
We have identified that a major factor contributing to prolonged healing of wounds is the
development of paradoxical reactions and this is independent of the size of the lesion at com-
mencement of antibiotic treatment. Therefore, measures to prevent or minimise them would
appear important when trying to improve wound healing. We know that paradoxical reactions
are more likely to occur in those who are 60 years of age, have oedematous lesions and have
used amikacin in their antibiotic regimen,[13] but little data is available on how we can prevent
them or minimise their adverse effects on wound healing. We have reported success in pre-
venting or minimising tissue necrosis associated with paradoxical reactions using corticoste-
roids but this needs further study to confirm our findings.[14, 15]
Another important factor affecting wound healing times is the size of lesions at commencement
of antibiotic treatment. To improve wound healing times there is thus an urgency to diagnose
lesions at an earlier stage of disease. Community campaigns aimed at increasing the awareness of
M. ulcerans and the importance of early diagnosis need to be implemented and linked to medical
education facilitating clinicians to recognise and diagnose early M. ulcerans lesions.[16] This
includes atypical forms of the disease such as oedematous and nodular lesions.[2]
In our study we have shown that surgical treatment of lesions with excision and direct clo-
sure may reduce healing times for category A or B lesions by an average 1–2 months compared
to using antibiotics alone. Additionally, we report that surgical curetting of small lesions (Cate-
gory A) results in similar healing times to those of similar size treated with antibiotics alone.
However, based on our published experience of successful outcomes with the combination of
surgery and shortened antibiotic treatment durations,[17] in this study we found that both of
these above surgical options have the additional advantage of permitting significantly shorter
antibiotic courses (an average reduction of half the duration) to be used without affecting
treatment success rates, with the potential to reduce antibiotic related treatment toxicity.[18]
Therefore this provides clinicians in settings with access to appropriate surgical services an
additional treatment option to antibiotics alone for small lesions that may reduce healing
times and antibiotic toxicity. Surgical debridement was not associated with reduced healing
times, but any beneficial effect may have been confounded by the fact that the majority of
cases where it was used (75%) also experienced paradoxical reactions which would have biased
the sample towards prolonged healing. Therefore it is possible that if the cohort had been
matched for the occurrence of paradoxical reactions there may have been a beneficial effect on
wound healing time for those who had surgical debridement. This needs further study.
Although in a small proportion of patients wound healing took longer than 12 months, it is
important to note that in all such cases wounds eventually healed without further antibiotic
treatment. This suggests there are a proportion of lesions that will have very prolonged healing
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times, possibly influenced by low-grade paradoxical reactions which were present in all cases,
and in these situations significant patience may be needed on the part of clinicians and
patients.
Prolonged healing times can lead to significant patient and clinician dissatisfaction. There-
fore there is an urgent need to develop new interventions aimed at improving healing times.
[19] Such options could include the use of agents that target the mycolactone toxin of M. ulcer-
ans in order to minimise tissue destruction associated with lesions, improved dressing regi-
mens and wound care techniques such as negative pressure wound therapy,[20] debridement
of wounds with medical maggot debridement therapy,[21] more aggressive surgical debride-
ment techniques, and interventions to prevent paradoxical reactions.[15]
The main limitation of this study is its observational nature where treatment interventions
were not randomised. As a result, we cannot make firm conclusions regarding the effectiveness
of interventions such a surgical treatment on wound healing rates. In addition, there may have
been unrecognised confounders that were not controlled for in the multivariable analysis of
risk factors for prolonged wound healing. Nevertheless, the associations with lesion size and
paradoxical reactions were very strong and thus we feel that it is unlikely that this would have
significantly affected these findings.
Conclusions
We have described the natural history in response to antibiotic treatment of M. ulcerans lesions
in Australian patients, and have shown that lesions usually initially clinically improve, and then
deteriorate with increased induration and ulceration, prior to healing after the inflammation
associated with the lesions resolves. The time to complete healing of lesions is generally long,
and is further prolonged in those with increasing initial size of lesions or who develop paradoxi-
cal reactions. For small lesions (<4cm2), excisional surgery can reduce healing times.
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